Trial Profile
A Phase II Randomized Study of Enzalutamide+Leuprolide Versus Enzalutamide+Leuprolide+Abiraterone Acetate+Prednisone as Neoadjuvant Therapy for HIgh-Risk Prostate Cancer Undergoing Prostatectomy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2022
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Abiraterone acetate; Leuprorelin; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 30 Mar 2022 Status changed from active, no longer recruiting to completed.
- 13 Feb 2021 Results of pooled analysis of post-RP outcomes from four clinical trials (NCT00298155; NCT00924469; NCT01547299; NCT02268175) presented at the 2021 Genitourinary Cancers Symposium
- 24 May 2019 Planned primary completion date changed from 1 Dec 2018 to 1 May 2019.